ライフサイエンスコーパス: company

1 ountries dominated by a single search engine company.

2 diary of Takeda Pharmaceutical International Company.

3 among the U.S. EPA, EPRI, EERC, and Southern Company.

4 nimidyl) propionate, developed by the CovalX Company.

5 avior that emerge when single molecules have company.

6 , a wholly owned subsidiary of Eli Lilly and Company.

7 idges were left by the pipeline construction company.

8 ther that this is driven by small indigenous companies.

9 ograms have voluntarily been put in place by companies.

10 ntists hoping to partner with pharmaceutical companies.

11 on, now part of the GlaxoSmithKline group of companies.

12 and 7 are currently marketed by 1 of 3 large companies.

13 nd and build successful therapeutics-focused companies.

14 , professional organizations, and diagnostic companies.

15 m discovery programs in major pharmaceutical companies.

16 ntrolled (73%) and involved 32 drugs from 24 companies.

17 and funded by African institutes and private companies.

18 anizations or reimbursed by health insurance companies.

19 d data commonly available in most large drug companies.

20 dical device, diagnostics, and biotechnology companies.

21 ether with pharmaceutical venture capitalist companies.

22 rsued both in academia and in pharmaceutical companies.

23 calTrials.gov and websites of pharmaceutical companies.

24 nder the control of essentially two breeding companies.

25 leted studies sponsored by 13 pharmaceutical companies.

26 attracted much interest from pharmaceutical companies.

27 marketing environments for food and beverage companies.

28 lities of research centres and biotechnology companies.

29 the scientific community and pharmaceutical companies.

30 ive substantial support from drug and device companies.

31 nder investigation in various pharmaceutical companies.

32 hrough collaborations with 18 pharmaceutical companies.

33 rganisms, fostering a new crop of anti-aging companies.

34 to raw genomic data using direct-to-consumer companies.

35 , and donations of drugs from pharmaceutical companies.

36 nvestors, which is especially apparent among companies.

37 tion among farmers, plant breeders, and seed companies.

38 ons, and that lower enforcement attracts all companies.

39 2012) of the global total, as did that of US companies (50% to 41%), with the total US (public plus p

40 a delicatessen meat (spiced meat roll) from company A was identical to the outbreak strain.

41 Products from company A were traced and recalled from >6000 food estab

42 onalized; institutions were supplied food by company A.

43 based businesses, particularly biotechnology companies, a PhD in the life sciences can be very helpfu

44 Contributions from large companies, academia and high-tech start-ups are used to

45 lobal medical evidence software and services company, across PubMed and EMBASE from 1966 to 2015 usin

46 arly molecular diagnostics, and well over 50 companies actively engaged in product development.

47 74 off-label promotion rulings involving 43 companies and 65 drugs.

48 sis was limited to the direct cost of HIV to companies and did not examine the impact of HIV preventi

49 r this dataset by embedding the positions of companies and directors in a latent space.

50 CNT manufacturing companies and downstream users of CNTs will benefit from

51 iduals prefer to keep their connections with companies and funds.

52 , we combined data from three pharmaceutical companies and generated ADMET rules, avoiding the need t

53 i) > 0.999 98 mol/mol), recently produced by companies and institutes in Russia within the framework

54 also as a source of knowledge for insurance companies and other institutions involved in the cost re

55 Pharmaceutical companies and other trial sponsors must submit certain t

56 and make comparisons between countries, food companies and over time.

57 atives analysis would advance the ability of companies and regulators to select alternatives to harmf

58 The use of R. toruloides by companies and research groups has exponentially increase

59 ies 99.0%, commercial samples from different companies and Stevia rebaudiana Bertoni leaves from Para

60 acilitating collaboration between diagnostic companies and the ARLG Master Protocol for Evaluating Mu

61 protocol discussions between pharmaceutical companies and the FDA in advancing the development of pr

62 poral bipartite network of the leading Irish companies and their directors from 2003 to 2013, encompa

63 g nodule abundance is of interest for mining companies and to monitor potential environmental impact.

64 ds with better properties than do big pharma companies and universities.

65 9 were extracted from a healthcare insurance company and compared to an age and gender matched contro

66 Eli Lilly and Company and ImClone Systems LLC, a wholly owned subsidia

67 ibe how partnering works in a pharmaceutical company and offer advice on how to make a successful tra

68 DCAT from the perspectives of the sponsoring company and participating sites are discussed.

69 The success of the company and the institute allowed me to undertake severa

70 tfolio manager in a larger biopharmaceutical company and the skills from academic research I leverage

71 te partnership between Becton, Dickinson and Company and the US President's Emergency Plan for AIDS R

72 o the water inlet of a drinking water supply company and their possible adverse public health effects

73 lated from further samples taken within this company and within companies in its distribution chain.

74 ere initially developed by small to midsized companies, and 7 are currently marketed by 1 of 3 large

75 y sensitive to the presence of a few outlier companies, and confirm that nearly all biotech companies

76 presentatives from health systems, insurance companies, and industry-to understand barriers to care d

77 of commercial vaccines by the pharmaceutical companies, and participation of many patient volunteers

78 -setting bodies, governments, pharmaceutical companies, and philanthropic organizations.

79 across many different contexts: Governments, companies, and political parties use persuasive appeals

80 this type will help planners, transportation companies, and society at large to shape a sustainable p

81 LBI, patient advocacy groups, pharmaceutical companies, and the U.S. Food and Drug Administration to

82 t healthcare costs, loss of revenue for food companies, and--in the worst cases--death.

83 Millennium Pharmaceuticals, Takeda Oncology Company, and Celgene Corporation.

84 Mort database and other sources at the town, company, and individual level to assess the relation bet

85 MVP chose to become a "virtual vaccine company," and over the next decade managed a network of

86 While many companies are active in the field, scientists engaged in

87 se reasons, investigators and pharmaceutical companies are actively exploring novel strategies to ant

88 t fashion" and "lean manufacturing," so that companies are better able to deliver products consumers

89 By contrast, other pharmaceutical companies are developing microbial vectors that deliver

90 Biopharma companies are increasingly adopting Quality by Design (Q

91 Second, since companies are increasingly obliged to quantify the envir

92 ayers, medical societies, and pharmaceutical companies are increasingly utilizing healthcare data to

93 At the same time, big pharmaceutical companies are losing interest in new antibiotics develop

94 mpanies, and confirm that nearly all biotech companies are loss-making enterprises, exhibiting high s

95 Pharmaceutical companies are reducing their investments in research, an

96 d insufficient investments by pharmaceutical companies are some of the clear reasons behind market fa

97 r investments in research, and biotechnology companies are struggling to obtain venture funds.

98 with a shrinking domestic market, many coal companies are taking advantage of a growing coal export

99 d it is thus unsurprising that some analytic companies are turning attention to problems in health ca

100 since ceria was first employed by Ford Motor Company as an oxygen storage component in car converters

101 Institute of Health Research, The Medicines Company, AstraZeneca, The Bentley Drivers Club (UK).

102 inrich Caro, Director of the German chemical company Badische Anilin- und Soda-Fabrik.

103 The objective of the Becton, Dickinson, and Company (BD)-US President's Emergency Plan for AIDS Reli

104 There is an intense activity in many companies both on expanding the utility of JAK inhibitor

105 As pharmaceutical companies bring more fully humanized therapeutic mAb dru

106 ties offered by gold mining and agricultural companies but continue to depend on forests for house co

107 nts, such as Scotchgard fabric protector (3M Company), can be metabolically degraded, using a model m

108 In parallel, the number of companies centered on applying complex data analysis to

109 d some possibly relevant documents.) Tobacco companies considered the IOM report to have high-stakes

110 of 11 ocular nutritional supplements on the companies' consumer information websites; the ingredient

111 rms can create conditions that incentivize a company, country, or individual to fish sustainably, cur

112 riatal signaling, and several pharmaceutical companies currently investigate PDE10A inhibitors in cli

113 Multiple pharmaceutical companies currently test CDK4/6 inhibitors in combinatio

114 rovision, with the annual cost of HIV to the company decreasing by 5% (90% credibility interval [CrI]

115 As pharmaceutical companies develop fewer truly novel agents for treatment

116 On the basis of these data, pharmaceutical companies developed many Met inhibitors, some of which a

117 ol and Prevention, and Becton, Dickinson and Company developed a public-private partnership (PPP).

118 Three pharmaceutical companies developing CDI treatments came together to see

119 Support from major biopharmaceutical companies, development of hydroponic production systems,

120 e evolution of company interlocks, whereby a company director simultaneously sits on two or more boar

121 h descriptions in the corresponding internal company documents (i.e., what was planned and what was d

122 For each trial, we compared internal company documents (protocols, statistical analysis plans

123 ses conducted did not agree between internal company documents and what was publicly reported.

124 Internal company documents provide extensive documentation of met

125 ncept to viable technologies adopted by some companies due to significant improvements in the field.

126 Several major diagnostic companies either have products on the market or are curr

127 codes) were matched 1:1 by sex, age, region, company, employment status, and index date with controls

128 erlying risk/reward calculus could help keep companies engaged in making CNS drugs.

129 ving enzyme 1 (BACE-1), with many big pharma companies expending great resources in the search for BA

130 r analysis shows that mining and hydrocarbon companies fail to factor in the full scale of the costs

131 entities, including private health insurance companies, federal payers, medical societies, and pharma

132 ns (FDA); and supplementary information from company filings, press releases, and media reports.

133 Pharmaceutical companies find drug development programs increasingly co

134 nces and contacted respective pharmaceutical companies for additional studies.

135 o basic research laboratories and diagnostic companies for research and development, facilitating col

136 k the performance of 1,066 biopharmaceutical companies from 1930 to 2015-the most comprehensive finan

137 European Union law prohibits companies from marketing drugs off-label.

138 r accuracy, determine whether pharmaceutical companies from which the authors received payments manuf

139 belonging to a large, national managed care company from January 1, 2005, to December 31, 2012.

140 ance plans at a large US managed health care company from January 1, 2008, through February 29, 2016.

141 rs among shareholders, who are classified as companies, funds and individuals.

142 ns, our results suggest that a search engine company has the power to influence the results of a subs

143 A majority of the largest biopharmaceutical companies have announced strategic partnerships with a s

144 In contrast, since 2000, pharmaceutical companies have become increasingly profitable, with risk

145 Many pharmaceutical companies have been active in the search for GPR119 agon

146 Several academic groups and pharmaceutical companies have been developing a series of non-steroidal

147 Pharmaceutical companies have considerable flexibility in how they pric

148 protein surface, and several pharmaceutical companies have developed compounds and performed clinica

149 veral major pharmaceutical and biotechnology companies have disclosed RORc inhibitors or partnered wi

150 d as clinical researchers and pharmaceutical companies have focused their efforts on developing safe

151 ons of in-house facilities by pharmaceutical companies have had media channels pronouncing that RNAi

152 Several large pharmaceutical companies have selectively downsized their neuroscience

153 Transnational tobacco companies have sought to undermine tobacco tax policy by

154 Commercial companies have sprung up in a similar manner to the soft

155 is method includes the fact that the tobacco companies have withheld some possibly relevant documents

156 uick-service restaurant chains, or fast-food companies, have agreed to depict healthy foods in their

157 hat all therapies-often drugs from different companies-have to be available at the same time when the

158 e to deflect attention from SP and excluding company-held evidence relevant to SP.

159 nfluenced project design and relations among companies, host governments, and locally impacted commun

160 This work culminated in numerous companies identifying potent selective inhibitors, some

161 ation via a large statutory health insurance company (ie, insurance funded by joint employer-employee

162 a community, alleles at a genetic locus, and companies in a market are characterized by competition (

163 s are not designed for use by pharmaceutical companies in drug promotion.

164 s are not designed for use by pharmaceutical companies in drug promotion.

165 s are not designed for use by pharmaceutical companies in drug promotion.

166 The interest of tobacco companies in genetic information as well as the success

167 rkplace ART provision can be cost-saving for companies in high HIV prevalence settings due to reducti

168 samples taken within this company and within companies in its distribution chain.

169 hich may help guide future investigators and companies in streamlining eligibility criteria in the er

170 IV impacts heavily on the operating costs of companies in sub-Saharan Africa, with many companies now

171 from 4 machinery and equipment manufacturing companies in Taichung, Taiwan, was followed from 1973 to

172 terest from both academia and pharmaceutical companies in the discovery and development of druglike H

173 ants of investment decisions by agricultural companies in the Gran Chaco and Chiquitano, a region tha

174 ducted in 2011 and 2012 by a private housing company in about 1,800 apartments.

175 llions of data points) from the largest taxi company in Singapore suggests that there is an explicit

176 he cost-benefit of ART provision in a mining company in South Africa between 2003 and 2022.

177 on between the daily number of mentions of a company in the Financial Times and the daily transaction

178 8,906 users of Airbnb, a leading hospitality company in the sharing economy.

179 The approach described has been used at our company in various stages of discovery since 2001.

180 ly e-waste have been realized in specialized companies, in China, and law enforcement for illegal act

181 ptions of tobacco use, peer use, and tobacco-company influences.

182 We focus on the evolution of company interlocks, whereby a company director simultane

183 e to the continual decline of pharmaceutical companies investing in new antibiotic development and th

184 ket that may discourage major pharmaceutical company investment.

185 of the very large exchange of knowledge, all companies involved synergistically gained approximately

186 The performance of all biopharmaceutical companies is subject not only to factors arising from th

187 It is distinguished primarily by 'the company it keeps'.

188 nufactures, vendors, and commercial cleaning companies, it is time for a multifaceted intervention.

189 Yet companies know much less about the environmental and soc

190 nce: one on the model parameters, one on the companies' latent positions, and one on the edges themse

191 exchange on a global level, sharing-economy companies leverage interpersonal trust between their mem

192 ly owned subsidiary of Takeda Pharmaceutical Company Limited.

193 Agribusiness companies linking these frontiers to distant spaces of c

194 ime target of off-label promotion, competing companies lodged the majority of complaints (prescriber:

195 invasive laser flare cell meter FC-500 (Kowa Company Ltd, Tokyo, Japan), whereas SCT was evaluated by

196 Companies make decisions about the safety of some food c

197 All payments to dermatologists from companies making products reimbursed by a government-run

198 n authors have FCOIs with the pharmaceutical company marketing that drug.

199 xcess of the $50000 net and/or $20000 single-company maximums stipulated by NCCN.

200 complaints (prescriber: n = 16, 22%, versus companies: n = 42, 57%).

201 ompared with that among employees from other companies not offered the tool (n=295,983) in the year b

202 ed patient is set by the patient's insurance company-not the manufacturer, distributor, or pharmacy-a

203 f companies in sub-Saharan Africa, with many companies now providing antiretroviral therapy (ART) pro

204 In February 2016, The Company of Biologists hosted an intimate gathering of le

205 ng on both plant and animal systems met at a Company of Biologists workshop to discuss 'Coordinating

206 At a recent Company of Biologists Workshop, 'Evolution of the Human

207 tion gathered in late September 2016 for The Company of Biologists' second 'From Stem Cells to Human

208 gathered at Wotton House near London for the Company of Biologists' workshop 'From Stem Cells to Huma

209 in 22 common clinical lab tests between one company offering blood tests obtained from finger prick

210 Among employees at 2 large companies, offering a price transparency tool was not as

211 Brain Resource Company Operations Pty Ltd and NIH.

212 violations relies largely on complaints from company outsiders, which may explain why most off-label

213 marketing campaigns that remain concealed to company outsiders.

214 ucted at Hoffmann-La Roche and Eli Lilly and Company over the course of 8+ and 15+ years respectively

215 The companies' overall argument was that the SP evidence bas

216 to assess the relation between the dominant company ownership of a town and mortality.

217 chnology was disseminated through a spin-off company, Oxford GlycoSystems, and by the establishment o

218 cation sequence was generated by an external company; patients were randomly assigned (1:1:1) to rece

219 gh there is limited evidence to suggest that company performance on employer health management scorec

220 e from shipping companies that, according to company policy or federal regulation, do not ship cigare

221 d reward of investments in biopharmaceutical companies poses a challenge to those interested in fundi

222 7 knock-out mice generated by pharmaceutical companies possess certain splice variants, which evade i

223 was broad consensus that drug and insurance companies' profits added to costs, although physicians,

224 te disclosure statement accuracy, detail the companies providing payments, and evaluate Administrativ

225 ncial incentives and targeted programs among companies, public utility commissions, and scientists to

226 drawing on experience gained from working in companies ranging in size from four to more than 80,000

227 The company recalled 39 million cans of chili.

228 Medical communication companies receive substantial support from drug and devi

229 Many pharmaceutical companies recognise the advantages of revealing some pro

230 e (low, medium, and high) were obtained from company records.

231 Manufacturing companies routinely use copper fibers for blanket fabric

232 d on shared data compared to both individual companies' rules and rules published in the literature.

233 he Mexican urban population from The Nielsen Company's Mexico Consumer Panel Services (CPS).

234 These discoveries are then included in a company's pipeline and help bring novel treatments to pa

235 than offering a $25 monetary incentive, the company's previous policy.

236 Times and the daily transaction volume of a company's stock both on the day before the news is relea

237 Dutch College of Health Insurance Companies, Schering-Plough, and Janssen.

238 We test whether companies seek out less-regulated forest areas for new a

239 pose significant health care problems, drug companies seldom develop drugs for orphan diseases due t

240 enefits of these drugs, and health insurance companies should provide reasonable coverage for their u

241 Energy companies should respect a safe distance from major natu

242 h medium binding surfaces from two different companies showed an approximately 2-fold difference in c

243 ately insured individuals in 69 self-insured companies spanning diverse industries.

244 Company-sponsored (Genentech or Novartis) studies in DME

245 Company-sponsored HIV counselling and voluntary testing

246 (Principles of Good Publication Practice for Company-Sponsored Medical Research, Data Sharing, Studie

247 onsumers (n = 3, 4%), payers (n = 2, 3%), or company staff (n = 2, 3%).

248 tinued monitoring is warranted owing to food companies' stated intentions to increase marketing to Hi

249 Tobacco companies strategically interacted with the IOM to win s

250 rol subjects) and the Janssen-Brain Resource Company study (94 patients and 100 control subjects).

251 If even one company succeeds, however, the impact will be huge.

252 Gene therapy companies that pursue high, one-time payments for their

253 restation regulations attract investments by companies that tend to clear more forest, mostly cattle

254 All delivered packages came from shipping companies that, according to company policy or federal r

255 tive agent of skin changes in employees of a company that produced herbal medicines.

256 July and August of 2012 while working for a company that produced herbal medicines.

257 portive supervision, using Magpi software (a company that provides service to collect data using mobi

258 sis Critical Control Point system by seafood companies, the number of seafood-related foodborne illne

259 by New England Biolabs, the Cayman Chemical Company, the Rackham Graduate School and the University

260 lopment, as it would pressure pharmaceutical companies to become more innovative and avoid the develo

261 many efforts of several worldwide commercial companies to bring functional MOFs towards the daily use

262 ir prescriptions and will aid pharmaceutical companies to design large-scale clinical trial by assess

263 tive market models are needed to incentivize companies to invest in developing new antibacterial drug

264 collected information from current operating companies to perform a process LCA of production for MS

265 priate to encourage small, medium, and large companies to reinvest in this space.

266 e distribution of funds from drug and device companies to various entities and assess the characteris

267 chase attempts, with no attempts by delivery companies to verify their ages at delivery and 95% of de

268 We collaborated with a utility company to study participation in a program designed to

269 ds, was intended to be proposed by Agroforex Company to the Codex Committee on Food Additives for eva

270 ), a commercially available credit reporting company, to construct residential histories for particip

271 Based on interviews with 82 companies totaling 2.5 Mha of properties, we show that,

272 rocess by Taiwan Semiconductor Manufacturing Company (TSMC).

273 paper aims to explore transnational tobacco company (TTC) interests in SLT and pure nicotine in Euro

274 rol measure opposed by transnational tobacco companies (TTCs) whose responses to the UK government's

275 Pharmaceutical companies typically perform prospective, multicenter pha

276 Many companies use life cycle assessment (LCA) to evaluate th

277 Food companies use precautionary allergen labels to inform al

278 Every year pharmaceutical companies use significant resources to mitigate aggregat

279 ndustry documents suggest at least one other company used a similar approach.

280 onsent was not obtained and a pharmaceutical company used data for marketing (weighted mean appropria

281 r payments to ophthalmologists by biomedical companies was reviewed for representation, median paymen

282 on (now part of the GlaxoSmithKline group of companies), Wellcome Trust UK, Medical Research Council:

283 The top 15 companies were all pharmaceutical manufacturers and paid

284 Only a few years ago pharmaceutical companies were excited about the potential of RNA interf

285 t the influence of the tobacco industry, the companies were pleased with the final report, particular

286 Nineteen companies were ruled in breach more than once, and ten c

287 were ruled in breach more than once, and ten companies were ruled in breach three or more times over

288 April 2013 explosion at the West Fertilizer Company (WFC) that resulted in 15 fatalities, more than

289 r, with the pharmaceutical and fine-chemical companies which utilize these reactions.

290 erated by the American Smelting and Refining Company, which could have provided the Pb used in the te

291 posed workers (controls) at one shipbuilding company who were enrolled in August-December of 2012.

292 ted (90-98%) by a few internationally active companies whose cultivation models were almost exclusive

293 Authors received payments from companies with products directly related to the guidelin

294 rojects to a recently formed Hong Kong based company with no track record or related expertise.

295 s the positioning of Litopterna (possibly in company with other SANU groups) as a separate order with

296 Myriad Genetics, a company with patents on BRCA1 and BRCA2, two genes criti

297 nalysis and analysed ownership data from 262 companies within these towns.

298 The fiduciary responsibilities of companies working in Africa should include the effective

299 the interest of multi-billion dollar pharma companies worldwide for further developments of SPI syst

300 or distinguishing biotech and pharmaceutical companies yields a dynamic, more accurate classification